Video

Dr. Abid on Adaptive Lymphodepletion in CAR T-Cell Recipients in R/R B-Cell NHL

Muhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.

Muhammad Bilal Abid, MD, MRCP, assistant professor of medicine, Divisions of Hematology/Oncology and Infectious Diseases, Medical College of Wisconsin, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) who received CAR T-cell therapy.

This evaluation compared toxicity outcomes in adult patients with relapsed/refractory B-cell NHL between June 2018 and August 2020 who received 2 intensities of lymphodepletion chemotherapy. Patients either received the standard dose of lymphodepletion at 30 mg/m2 of fludarabine and 500 mg/m2 of cytarabine per day for each for 3 days prior to receiving axicabtagene ciloleucel (axi-cel; Yescarta), or a lower-dose of 30 mg/m2 of fludarabine for 3 days and 500 mg/m2 of cytarabine for 1 day.

Patients in the low-dose lymphodepletion cohort had a median duration of lymphopenia of 5 days, compared with a median duration of lymphopenia of 11 days in patients who received standard-dose lymphodepletion, Abid says. Moreover, 50% of patients in the low-dose cohort experienced episodes of neutropenic fever in the first 28 days, vs 85% in the standard-dose cohort, Abid explains.

Risk of neurotoxicity, such as cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, were significantly less in the low-dose cohort, Abid adds. As a result, the use of corticosteroids and tocilizumab (Actemra) was less in the low-dose cohort, Abid concludes.

Related Videos
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Shaji Kumar, MD
Kevin Kalinsky, MD, MS
Guru P. Sonpavde, MD
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD